JP2023548046A - 抗ｃ５抗体を使用する、補体障害を有する患者の処置方法 - Google Patents

抗ｃ５抗体を使用する、補体障害を有する患者の処置方法 Download PDF

Info

Publication number
JP2023548046A
JP2023548046A JP2023524629A JP2023524629A JP2023548046A JP 2023548046 A JP2023548046 A JP 2023548046A JP 2023524629 A JP2023524629 A JP 2023524629A JP 2023524629 A JP2023524629 A JP 2023524629A JP 2023548046 A JP2023548046 A JP 2023548046A
Authority
JP
Japan
Prior art keywords
antibody
seq
dose
patient
patients weighing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023524629A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023548046A5 (enExample
Inventor
クリスタ ケー． ジョンソン，
ポール ピー． タンブリーニ，
ダグラス エル． シェリダン，
Original Assignee
アレクシオン ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アレクシオン ファーマシューティカルズ， インコーポレイテッド filed Critical アレクシオン ファーマシューティカルズ， インコーポレイテッド
Publication of JP2023548046A publication Critical patent/JP2023548046A/ja
Publication of JP2023548046A5 publication Critical patent/JP2023548046A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/47—Scattering, i.e. diffuse reflection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/47—Scattering, i.e. diffuse reflection
    • G01N2021/4704—Angular selective
    • G01N2021/4711—Multiangle measurement
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N2030/022—Column chromatography characterised by the kind of separation mechanism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2023524629A 2020-10-23 2021-10-22 抗ｃ５抗体を使用する、補体障害を有する患者の処置方法 Pending JP2023548046A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063105018P 2020-10-23 2020-10-23
US63/105,018 2020-10-23
PCT/US2021/056153 WO2022087339A1 (en) 2020-10-23 2021-10-22 Methods of treating patients having complement disorders using anti-c5 antibodies

Publications (2)

Publication Number Publication Date
JP2023548046A true JP2023548046A (ja) 2023-11-15
JP2023548046A5 JP2023548046A5 (enExample) 2024-10-29

Family

ID=78695818

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023524629A Pending JP2023548046A (ja) 2020-10-23 2021-10-22 抗ｃ５抗体を使用する、補体障害を有する患者の処置方法

Country Status (5)

Country Link
US (1) US20240018220A1 (enExample)
EP (1) EP4232473A1 (enExample)
JP (1) JP2023548046A (enExample)
CA (1) CA3196434A1 (enExample)
WO (1) WO2022087339A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3024618A1 (en) 2016-05-27 2017-11-30 Alexion Pharmaceuticals, Inc. Methods for treatment of refractory generalized myasthenia gravis
JP7518764B2 (ja) 2017-10-26 2024-07-18 アレクシオン ファーマシューティカルズ， インコーポレイテッド 発作性夜間ヘモグロビン尿症（ＰＮＨ）および非典型溶血性尿毒症症候群（ａＨＵＳ）の処置のための抗Ｃ５抗体の投薬量および投与
EP3802593B1 (en) 2018-05-31 2024-09-11 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) in pediatric patients
WO2026101219A1 (ko) * 2024-11-06 2026-05-15 주식회사 이뮨앱스 보체 c5 결합 단백질

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
JP2010500876A (ja) 2006-08-18 2010-01-14 アブリンクス エン．ヴェー． Ｉｌ−６媒介性シグナル伝達に関連する疾患及び障害の治療のための、ｉｌ−６ｒに指向性を有するアミノ酸配列及びこれを含むポリペプチド
PY09026846A (es) 2008-08-05 2015-09-01 Novartis Ag Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
NZ711451A (en) 2014-03-07 2016-05-27 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
EA201791366A1 (ru) 2014-12-19 2018-02-28 Чугаи Сейяку Кабусики Кайся Антитела к c5 и способы их применения
IL263481B2 (en) 2016-06-14 2024-06-01 Regeneron Pharma Anti-c5 antibodies and uses thereof
TWI828672B (zh) * 2017-01-31 2024-01-11 日商中外製藥股份有限公司 用於治療或預防c5相關疾病的醫藥組合物以及治療或預防c5相關疾病的方法
JP7518764B2 (ja) * 2017-10-26 2024-07-18 アレクシオン ファーマシューティカルズ， インコーポレイテッド 発作性夜間ヘモグロビン尿症（ＰＮＨ）および非典型溶血性尿毒症症候群（ａＨＵＳ）の処置のための抗Ｃ５抗体の投薬量および投与
AU2018383751B2 (en) * 2017-12-13 2025-05-08 Regeneron Pharmaceuticals, Inc. Anti-C5 antibody combinations and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J. CONE ET AL.: "Formation of multivalent complexes in the presence of more than one conventional antibody to complem", BRITISH JOURNAL OF HAEMATOLOGY, vol. 189, no. 1, JPN6025051644, 27 April 2020 (2020-04-27), pages 145 - 146, ISSN: 0005903040 *

Also Published As

Publication number Publication date
CA3196434A1 (en) 2022-04-28
EP4232473A1 (en) 2023-08-30
US20240018220A1 (en) 2024-01-18
WO2022087339A1 (en) 2022-04-28

Similar Documents

Publication Publication Date Title
KR102763158B1 (ko) 최적화된 항tl1a 항체
US20200165328A1 (en) Antibodies to Pyroglutamate Amyloid-B and Uses Thereof
WO2019062832A1 (zh) Tigit抗体、其抗原结合片段及医药用途
EP4232473A1 (en) Methods of treating patients having complement disorders using anti-c5 antibodies
WO2018177393A1 (zh) B7-h3抗体、其抗原结合片段及其医药用途
CN111138540A (zh) 治疗自身免疫疾病的结合fcrn的抗体
WO2019154315A1 (zh) 抗b7-h4抗体、其抗原结合片段及其医药用途
CN113166241B (zh) 人类znt8抗体
EA023406B1 (ru) Антитела к гепцидину и варианты их применения
CN107428822A (zh) 抗甲状腺素运载蛋白抗体
BR112020019647A2 (pt) Anticorpo anti-cd27, fragmento de ligação ao antígeno do mesmo e uso médico do mesmo
WO2021160116A1 (zh) 抗FcRn抗体、其抗原结合片段及其医药用途
CN112243443B (zh) 抗trop-2抗体、其抗原结合片段及其医药用途
JP2023548046A5 (enExample)
WO2021110095A1 (zh) 抗gpc3抗体、其抗原结合片段及其医药用途
JP2022528953A (ja) 抗タウｃ３抗体及びその使用
CN115298216A (zh) 抗体或其抗原结合片段、其制备方法及医药用途
CN108178798B (zh) pH工程化的NGF抗体及其医药用途
WO2018228406A1 (zh) Pcsk9抗体、其抗原结合片段及其医药用途
CN118317976A (zh) 针对FcγRIIA的结合分子及其应用
JP2016510870A (ja) 補体因子ｈ関連タンパク質１検出のための剤、キットおよび方法
WO2022078490A1 (zh) 抗erbb3抗体或其抗原结合片段及其医药用途
WO2023025249A1 (zh) 一种含融合蛋白的药物组合物
CN115109157A (zh) 抗体或其抗原结合片段，其制备方法及医药用途
WO2023198138A1 (zh) 抗体或其抗原结合片段及其医药用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241021

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241021

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251216

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260313

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260707